1 – 10 of 37
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
- Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays
- 2019
-
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A : Combined analysis of three studies
Volkers, Peter ; Hanschmann, Kay-Martin ; Calvez, Thierry ; Chambost, Hervé ; Collins, Peter W ; Demiguel, Virginie ; Hart, Daniel P ; Hay, Charles R M ; Goudemand, Jenny and Ljung, Rolf LU
, et al.
(2019)
In Haemophilia
25(3).
p.398-407
Mark
- Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B
- 2018
- Defining extended half-life rFVIII-A critical review of the evidence
- Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII
- Immune tolerance induction : What have we learned over time?
- 2017
- European retrospective study of real-life haemophilia treatment
- Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment
-
Primary prophylaxis in haemophilia care : Guideline update 2016
Fischer, Kathelijn and Ljung, Rolf LU
(2017)
In Blood Cells, Molecules, and Diseases
67.
p.81-85
Mark
- Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics